Key result
Higher human non-mercaptalbumin linked to ~12% increased risk of multivessel CAD.
Why the study?
Few reports have examined the association between human non-mercaptalbumin (HNA) and the severity of coronary artery disease (CAD).
Does human non-mercaptalbumin (HNA) level predict the severity of coronary artery disease in patients at high risk or suspected of having ACS?
Cross-Sectional (n=138)
No
Does human non-mercaptalbumin (HNA) level predict the severity of coronary artery disease in patients at high risk or suspected of having ACS?
HNA levels correlate with angiographic coronary artery disease severity and may serve as a biomarker for multivessel CAD.
HNA association with multivessel CAD is hypothesis-generating; leaves open its value for predicting severity in suspected ACS.
Human non-mercaptalbumin (HNA), oxidized form of serum albumin, has been reported as a useful marker in oxidative stress-related diseases; however, few reports have examined the association between HNA and the severity of coronary artery disease (CAD). The present study evaluated whether the HNA fraction is correlated with coronary artery stenosis in 140 patients considered to have a high risk of CAD or who were suspected of having acute coronary syndrome. The severity of CAD was defined by the number of stenotic coronary vessels and a severity score system (the Gensini score). HNA measurements were performed using our newly established high-performance liquid chromatography methodology. The results had shown that HNA was significantly increased in patients with three-vessel disease, compared with those without CAD or with single-vessel disease (p = 0.025), and was positively correlated with the Gensini score (ρ = 0.421, p < 0.001). A multivariate analysis showed that the number of stenotic vessels was an independent and significant factor associated with HNA (ρ = 1.246, p = 0.012). A logistic regression analysis showed that HNA was a strong predictor of multivessel CAD (odds ratio, 1.12; 95% confidence interval, 1.020-1.229; p = 0.017). These findings indicate that the measurement of HNA could be clinically practical for predicting the severity of coronary artery stenosis.
No takes yet. Share an insight, caveat, or question.
Chou et al. (2021) conducted a cross-sectional in Coronary artery disease (n=138). Human non-mercaptalbumin (HNA) vs. Lower HNA levels was evaluated on Multivessel coronary artery disease (OR 1.12, 95% CI 1.020-1.229, p=0.017). Higher levels of human non-mercaptalbumin were significantly associated with an increased risk of multivessel coronary artery disease (OR 1.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: